FOXP3 and non-small cell lung carcinoma: A prospective study involving 89 early-stage non-small cell lung cancer patients demonstrated that SBRT increased CD4+ and CD8+ T-cell levels and significantly changed transcription factors such as TBX21, GATA-3, and FOXP3.